We would like to inform you about the introduction of a new product in our coronary portfolio - Excrossal® drug-eluting stent (DES)
According to the results of a series of clinical trials by CREDIT, the Excrossal® drug-coated stent manufactured by JW Medical Systems (a division of Biosensors International) has proven effective and safe in the treatment of patients with coronary artery disease with primary coronary artery disease, with a low incidence of TLF and PoCE within 5 years after surgery.
Key Features:
Structure: It is a Cobalt-Chromium (CoCr) stent, which allows for thin struts while maintaining structural integrity.
Drug & Coating: It uses sirolimus (a medication that prevents tissue growth, reducing the risk of restenosis) with a biodegradable polymer coating. This coating breaks down over time, which can lead to better long-term vascular healing compared to permanent polymer stents.
Application: It is used in percutaneous coronary intervention (PCI) for patients with de novo coronary lesions (new blockages).
Performance: Studies, including the CREDIT II and III trials, indicate that Excrossal has a low incidence of Target Lesion Failure (TLF) and stent thrombosis over a 3-year period, similar to other widely used new-generation stents.
Clinical Standing: It has been used in clinical trials evaluating strategies for treating complex blockages, such as chronic total occlusions